# Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety Study

> **NCT04991805** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 14000 (actual)

## Conditions studied

- Asthma
- Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04991805
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-26
- **Primary completion:** 2024-04-05
- **Final completion:** 2024-04-05
- **Target enrollment:** 14000 (ACTUAL)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04991805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04991805, "Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04991805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*